Live
Lonza NewsLonza Group Ag (OTCMKTS:LZAGY) Short Interest Down 87.6% in March - MarketBeatCytiva (Google News)Yoshindo And Cytiva Strengthen Japan’s Biologics Sovereignty Through Scalable Modular Manufacturing - BioPharma APACWatersWaters Corporation stock faces uncertainty amid Trump national security alert and market volatility - AD HOC NEWSFierceBiotechIcon, Advarra partnership aims to optimize trials, expand accessAgilentAgilent Technologies Inc. stock rises on advanced chromatography solutions launch boosting lab effic - AD HOC NEWSLonza NewsLonza Group AG stock faces uncertainty amid board changes and biotech sector pressures in 2026 - AD HOC NEWSLonza NewsLonza Group AG stock faces pressure amid board changes ahead of 2026 annual meeting - AD HOC NEWS10x Genomics BlogVanguard amends 13G for 10X Genomics (NASDAQ: TXG) reporting 0 shares - Stock TitanCellPan-neurodegeneration proteomics reveals disease subtypes and molecular signaturesFierceBiotechMedtronic, Biotronik heart hardware make strides in conduction system pacingFierceBiotechGE HealthCare claims photon-counting CT clearance from FDACytiva (Google News)Cytiva-SR-TIGET Joint Venture Addresses Gene Therapy Bottlenecks - Inside Precision Medicine
Endpoints News Jan 6, 2026

Alumis' TYK2 drug succeeds in key psoriasis studies, will seek FDA approval

Alumis' TYK2 drug succeeds in key psoriasis studies, will seek FDA approval

Original
Body unavailable. Use the original source.

Directory

59 All